"We believe the combination of palatable clinical development risk, steady data/news flow, strong patent estate, and potential to meaningfully improve the treatment algorithm in an already greater than $1B HE market opportunity with a rapidly expanding patient demographic creates a highly favorable risk/reward at these levels," analyst Stephen Willey says.
Drugmaker Tranzyme (TZYM) +11.7% premarket on news it will explore a possible sale of the company, less than two years after it went public. Two mid-stage trials of its development drug for stomach paralysis recently were dropped due to lack of efficacy.
Tranzyme (TZYM) -66% premarket after reporting negative preliminary results from the first of two trials assessing its TZP-102 treatment for diabetic patients with a common stomach complication. Neither the 10mg dose group nor the 20mg dose group of TZP-102 patients reached statistical significance vs. a placebo.
Tranzyme Pharma (TZYM -65.9%) says a Phase 3 trial of its treatment to speed up gastrointestinal recovery following abdominal surgery failed to meet its primary endpoint. TZYM, which had planned to test ulimorelin in several additional indications, says it will stop all other activities related to the filing of a new drug application.
joeg1969+ FollowFollowing- Unfollow|Send Message10 Feb 2013
: Definetly !!!!!!!!!!!!Willl see how things play out for a bit before adding .......
joe kelly+ FollowFollowing- Unfollow|Send Message10 Feb 2013
: Bought some last week.
smokeyRose+ FollowFollowing- Unfollow|Send Message15 Nov 2012
Boy am i glad i sold my OCRX yesterday for $4.00 dropped to .99 cents today on Negative news. WOW!!!!
View all 2 replies
Ocean Man+ FollowFollowing- Unfollow|Send Message15 Nov 2012
: You posted 18 Stocktalks yesterday, yet failed to mention that....
smokeyRose+ FollowFollowing- Unfollow|Send Message16 Nov 2012
: Should I have? Had no idea it was going to do that. just lucky I guess
OCRX vs. ETF Alternatives
Ocera Therapeutics Inc is a clinical stage biopharmaceutical company. The Company is engaged in the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need.